Which has better valuation & earnings, PEPG or IPSC?

Century Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Century Therapeutics N/A N/A -$9.58M -$1.14 N/A

Is PEPG or IPSC more profitable?

Century Therapeutics' return on equity of -49.89% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Century Therapeutics N/A -49.89% -37.42%

Do analysts prefer PEPG or INDP?

PepGen currently has a consensus target price of $11.50, suggesting a potential upside of 538.89%. Given PepGen's stronger consensus rating and higher possible upside, research analysts clearly believe PepGen is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PEPG or INDP?

PepGen is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A

Is PEPG or INDP more profitable?

PepGen's return on equity of -59.89% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Indaptus Therapeutics N/A -1,030.07% -299.69%

Do analysts prefer CGC or PEPG?

PepGen has a consensus price target of $11.50, indicating a potential upside of 538.89%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Is CGC or PEPG more profitable?

PepGen has a net margin of 0.00% compared to Canopy Growth's net margin of -75.27%. Canopy Growth's return on equity of -26.95% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Canopy Growth -75.27% -26.95% -17.20% PepGen N/A -59.89% -49.62%

Which has stronger earnings and valuation, PEPG or MNPR?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A

Is PEPG or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Monopar Therapeutics N/A -12.84% -12.57%

Which has preferable earnings & valuation, EPRX or PEPG?

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is EPRX or PEPG more profitable?

PepGen's return on equity of -59.89% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -87.56% -51.20% PepGen N/A -59.89% -49.62%

PepGen (PEPG) Competitors

$1.80 -0.02 (-1.10%)

As of 10:10 AM Eastern

Compare

PEPG vs. IPSC, INDP, CGC, MNPR, and EPRX

Should you buy PepGen stock or one of its competitors? MarketBeat compares PepGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PepGen include Century Therapeutics (IPSC), Indaptus Therapeutics (INDP), Canopy Growth (CGC), Monopar Therapeutics (MNPR), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry.

How does PepGen compare to Century Therapeutics?

PepGen (NASDAQ:PEPG) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, PepGen's average media sentiment score of 0.00 equaled Century Therapeutics'average media sentiment score.

Company	Overall Sentiment
PepGen	Neutral
Century Therapeutics	Neutral

PepGen presently has a consensus price target of $11.50, suggesting a potential upside of 538.89%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 94.27%. Given PepGen's stronger consensus rating and higher possible upside, analysts plainly believe PepGen is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

58.0% of PepGen shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PepGen has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

Century Therapeutics' return on equity of -49.89% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Century Therapeutics	N/A	-49.89%	-37.42%

Century Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Century Therapeutics	N/A	N/A	-$9.58M	-$1.14	N/A

Summary

PepGen beats Century Therapeutics on 6 of the 11 factors compared between the two stocks.

How does PepGen compare to Indaptus Therapeutics?

PepGen (NASDAQ:PEPG) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

58.0% of PepGen shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PepGen currently has a consensus target price of $11.50, suggesting a potential upside of 538.89%. Given PepGen's stronger consensus rating and higher possible upside, research analysts clearly believe PepGen is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PepGen is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

PepGen has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

PepGen's return on equity of -59.89% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

In the previous week, Indaptus Therapeutics had 2 more articles in the media than PepGen. MarketBeat recorded 2 mentions for Indaptus Therapeutics and 0 mentions for PepGen. Indaptus Therapeutics' average media sentiment score of 0.46 beat PepGen's score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Neutral
Indaptus Therapeutics	Neutral

Summary

PepGen beats Indaptus Therapeutics on 8 of the 13 factors compared between the two stocks.

How does PepGen compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Canopy Growth has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, PepGen has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

In the previous week, Canopy Growth had 9 more articles in the media than PepGen. MarketBeat recorded 9 mentions for Canopy Growth and 0 mentions for PepGen. Canopy Growth's average media sentiment score of 0.04 beat PepGen's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Canopy Growth	Neutral
PepGen	Neutral

3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PepGen has a net margin of 0.00% compared to Canopy Growth's net margin of -75.27%. Canopy Growth's return on equity of -26.95% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-75.27%	-26.95%	-17.20%
PepGen	N/A	-59.89%	-49.62%

PepGen has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.52	-$190.29M	-$0.59	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

PepGen has a consensus price target of $11.50, indicating a potential upside of 538.89%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

PepGen beats Canopy Growth on 9 of the 15 factors compared between the two stocks.

How does PepGen compare to Monopar Therapeutics?

PepGen (NASDAQ:PEPG) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

PepGen has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

PepGen presently has a consensus target price of $11.50, indicating a potential upside of 538.89%. Monopar Therapeutics has a consensus target price of $107.91, indicating a potential upside of 28.03%. Given PepGen's higher possible upside, research analysts plainly believe PepGen is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Monopar Therapeutics' return on equity of -12.84% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Monopar Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

58.0% of PepGen shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Monopar Therapeutics had 1 more articles in the media than PepGen. MarketBeat recorded 1 mentions for Monopar Therapeutics and 0 mentions for PepGen. Monopar Therapeutics' average media sentiment score of 0.63 beat PepGen's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Neutral
Monopar Therapeutics	Positive

Summary

Monopar Therapeutics beats PepGen on 9 of the 14 factors compared between the two stocks.

How does PepGen compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Eupraxia Pharmaceuticals had 3 more articles in the media than PepGen. MarketBeat recorded 3 mentions for Eupraxia Pharmaceuticals and 0 mentions for PepGen. Eupraxia Pharmaceuticals' average media sentiment score of 0.52 beat PepGen's score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eupraxia Pharmaceuticals	Positive
PepGen	Neutral

Eupraxia Pharmaceuticals presently has a consensus price target of $18.33, indicating a potential upside of 184.02%. PepGen has a consensus price target of $11.50, indicating a potential upside of 538.89%. Given PepGen's higher probable upside, analysts plainly believe PepGen is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

PepGen's return on equity of -59.89% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
PepGen	N/A	-59.89%	-49.62%

Eupraxia Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, PepGen has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

58.0% of PepGen shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

PepGen beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEPG vs. The Competition

Export

Metric	PepGen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$124.16M	$3.52B	$6.58B	$12.14B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-1.03	20.35	24.81	24.06
Price / Sales	N/A	331.06	552.47	123.81
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.84	8.36	10.77	6.51
Net Income	-$89.65M	$23.85M	$3.56B	$337.03M
7 Day Performance	5.88%	4.10%	1.97%	0.10%
1 Month Performance	19.21%	3.45%	1.45%	1.07%
1 Year Performance	29.50%	57.16%	31.07%	28.66%

PepGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEPG PepGen	2.3806 of 5 stars	$1.80 -1.1%	$11.50 +538.9%	+30.9%	$124.16M	N/A	N/A	30
IPSC Century Therapeutics	1.6588 of 5 stars	$2.30 +2.2%	$4.75 +106.5%	+319.1%	$405.80M	$109.16M	N/A	170	Gap Down
INDP Indaptus Therapeutics	1.1258 of 5 stars	$3.69 +3.1%	N/A	-73.5%	$405.41M	N/A	N/A	6	Gap Down
CGC Canopy Growth	1.4816 of 5 stars	$0.98 -1.7%	N/A	-20.5%	$404.12M	$225.65M	N/A	3,150	News Coverage Insider Trade
MNPR Monopar Therapeutics	1.9454 of 5 stars	$61.47 +2.8%	$107.91 +75.5%	+157.8%	$400.40M	N/A	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PEPG) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PepGen (PEPG) Competitors

PEPG vs. IPSC, INDP, CGC, MNPR, and EPRX

How does PepGen compare to Century Therapeutics?

Summary

How does PepGen compare to Indaptus Therapeutics?

Summary

How does PepGen compare to Canopy Growth?

Summary

How does PepGen compare to Monopar Therapeutics?

Summary

How does PepGen compare to Eupraxia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PepGen (PEPG) Competitors

PEPG vs. IPSC, INDP, CGC, MNPR, and EPRX

How does PepGen compare to Century Therapeutics?

Does the media prefer PEPG or IPSC?

Do analysts recommend PEPG or IPSC?

Do insiders & institutionals have more ownership in PEPG or IPSC?

Which has more volatility & risk, PEPG or IPSC?

Is PEPG or IPSC more profitable?

Which has better valuation & earnings, PEPG or IPSC?

Summary

How does PepGen compare to Indaptus Therapeutics?

Do institutionals and insiders have more ownership in PEPG or INDP?

Do analysts prefer PEPG or INDP?

Which has stronger earnings & valuation, PEPG or INDP?

Which has more volatility & risk, PEPG or INDP?

Is PEPG or INDP more profitable?

Does the media favor PEPG or INDP?

Summary

How does PepGen compare to Canopy Growth?

Which has more volatility & risk, CGC or PEPG?

Does the media refer more to CGC or PEPG?

Do insiders & institutionals have more ownership in CGC or PEPG?

Is CGC or PEPG more profitable?

Which has better earnings & valuation, CGC or PEPG?

Do analysts prefer CGC or PEPG?

Summary

How does PepGen compare to Monopar Therapeutics?

Which has more volatility & risk, PEPG or MNPR?

Do analysts rate PEPG or MNPR?

Is PEPG or MNPR more profitable?

Which has stronger earnings and valuation, PEPG or MNPR?

Do institutionals & insiders believe in PEPG or MNPR?

Does the media prefer PEPG or MNPR?

Summary

How does PepGen compare to Eupraxia Pharmaceuticals?

Does the media favor EPRX or PEPG?

Do analysts rate EPRX or PEPG?

Which has preferable earnings & valuation, EPRX or PEPG?

Is EPRX or PEPG more profitable?

Which has more risk and volatility, EPRX or PEPG?

Do insiders & institutionals have more ownership in EPRX or PEPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools